We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Biodynamics Plc | OBD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.29 | 3.30% | 9.09 | 16:35:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.80 | 8.70 | 8.94 | 9.09 | 8.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 13/3/2024 20:23 by bowerdean Although only sold 180 PSE tests to 9/2, the figure at 17/1 (see their results) was 144, so they’ve sold 36 tests in 23 days, which is 570 annualised and that’s before getting this latest slug of cash to increase sales force etc.To be able to buy OBD at 9p, which is 2p cheaper than the last placing when there had been no mention of any PSE test looks a bit of a bargain to me. |
Posted at 13/3/2024 19:32 by pj84 JAF111 not sure about II but on HL if you go into the account in which you hold the shares there is a corporate action symbol against OBD which isn't there for the other holdings and you click on that. Not sure if it might be similar. I also had a message about it in my HL messages. |
Posted at 25/2/2024 10:36 by smithie6 Uppompei wrote"Is this test just a combination of a PSA result and genetic screening? I know the two are used in the process but is the method patentable/unique or could it be done by any company with the right equipment, but OBD just happen to be the first?" Imo the answer is Yes. So, OBD does NOT have a test for prostate cancer, as some might think/hope. |
Posted at 20/2/2024 01:11 by bones698 At the end of the day they need to turn it into money and a profitable business and thus far are failing to do that. Many companies struggle at this stage to turn promise into cash and when they are so. Loss making like obd it means they are required to raise capital at ever lower prices. In this market that resits in an share price that gets hammered and ehyvobd is struggling as everyone knows its coming.Getting a deal with a large upfront payment at this stage is unlikely but a small one won't provide enough runeya to see a profit and so a rights issue is the most likely outcome at a big discount given the amount they are likely to require. Sad but true for many small companies atm |
Posted at 13/1/2024 19:41 by smithie6 So....is the OBD test simply a DNA/genome test...& not a prostate test AT ALL, despite the hype. & many companies are able to do DNA/genome tests So, OBD has no moat keeping out competition & protecting it's % margin. And OBD does not make or offer a prostate cancer test, despite the hype/P.R. ----- Can anyone justify/explain how/why I am wrong ? |
Posted at 20/11/2023 10:40 by hatfullofsky I also sent the following mail to OBD.I was pleased to read the article in the Daily Mail on 18th November, which is great news for the patient and possibly good news for OBD. I am a shareholder of OBD and would like to know if OBD's PSE test will be included in the the TRANSFORM screening pilot ? I would also like to hear your views of how this screening proposal may effect the adoption of the PSE test ? Clearly if there is a preferred screening approach that does not include the PSE test it would be hard to gain test adoption. Regards |
Posted at 26/10/2023 15:46 by smithie6 Blah blah blah.OBD has not created a yes/no test for prostate cancer. Full stop. If it had its share price would be much higher. ....if potential shareholders need to first have a degree in human pharma stuff & read the OBD test reports & understand words like "epigenetic biomarkers" Then the number of potential shareholders in the UK where OBD is listed is quite small. I'm not interested to devote the time to learn about all this medical jargon such as "epigenetic biomarkers". I note the words genetic & surveillance of people that have been tested. If OBD come up with a yes/no test for prostate cancer then I would be interested to again buy/hold some shares. ----- Usual low quality of posts on ADVFN. 'you don't like the shares so I'm going to slag you off' Infers that some posters are not very shrewd/wise. |
Posted at 18/10/2023 15:21 by givmesunshine From a kind poster on LSE Broker NoteOBD/BUPA partnership for CiRT: OBD has announced this morning that the UK health insurer BUPA will offer OBD's immunotherapy susceptibility test (EpiSwitch CiRT) to cancer patients who are being considered for treatment with a checkpoint inhibitor. We believe that this partnership represents another important commercial validation of the potential of the CiRT test to identify those patients most likely to benefit from checkpoint inhibitor treatment. While the availability of the checkpoint inhibitor class has transformed the outlook for many cancer patients, offering the prospect of durable responses, efforts are ongoing to ensure that only patients who benefit receive treatment. Previously, the only predictive biomarkers approved for clinical use have been PD-L1 expression, tumour mismatch repair deficiency and high tumour mutational burden. However, their utility has been hampered by the lack of a standardised threshold and do not correlate well with response rates. We have previously highlighted the very real issue where, for example, patients with apparently low PD-L1 levels still respond to anti PD-L1 therapy, while many patients with tumours which have high PD-L1 expression levels, may not respond to PD-L1 or PD1 inhibition. Clearly, there is a need for a more accurate test to provide expected efficacy in individual cancer patients. OBD's EPISwitch CiRT test has the potential to be an important contributor, offering a potent mix of best-in-class predictive performance combining high sensitivity (93%), specificity (82%) and accuracy (85%) across 15 cancer types, without the need for invasive biopsies. |
Posted at 27/9/2023 10:33 by intoodeep OBD has previously highlighted its extensive pipeline of deployable molecular tests, in several disease areas, indicating that the most likely prospects for subsequent product development are in prostate and colorectal cancer screening, and canine lymphoma. This remains the case and we have been proceeding with internal and collaborative R&D work in these areas.In prostate cancer, for example, OBD is involved in a Prostate Cancer Research-funded project to develop a test to aid detection of prostate cancer in black men, who suffer both increased prevalence of, and mortality from, this disease compared to other groups. This work, carried out in conjunction with University of East Anglia (UEA) and Imperial College NHS Healthcare Trust builds on OBD's successful participation in the PROSTAGRAM trial. A forthcoming paper jointly written by OBD with Department of Surgery and Cancer, Imperial College, London; School of Medicine, University of East Anglia, Norwich; and King's Clinical Trials Unit, King's College London, entitled "Circulating chromosome conformation signatures significantly enhance PSA positive predicting value and overall accuracy for prostate cancer detection" sets out the exciting results of OBD's participation in the PROSTAGRAM trial. While prostate cancer has a high lifetime prevalence (1 in 6 men), there is no generally accepted screening programme. The widely-used prostate-specific antigen (PSA) test does not have sufficient accuracy, resulting in numerous unnecessary biopsies and false reassurances. EpiSwitch® results from the PROSTAGRAM trial demonstrate that combining a standard PSA readout with non-invasive EpiSwitch biomarkers in a Prostate Screening EpiSwitch (or "PSE") test results in significantly enhanced positive predictive value (PPV) and overall accuracy for prostate cancer detection, compared to the current PSA test. The Group will continue to prepare for the development and launch of subsequent commercial products. Whilst we will be ready to respond quickly to opportunities for commercialization in these areas, our plan is for the primary application of the Group's existing resources through 2023 to be in support of our flagship EpiSwitch® CiRT product. |
Posted at 26/9/2023 20:38 by smithie6 "25 million PSA tests in the US alone each year1% of that market produces $25m - $50m in revenue annually..." 1% !! Or 25 million OBD tests ? Why bother with a test that is only 54% accurate ....logical imo that the OBD test will just completely replace the existing PSA test. You infer that 1 OBD test costs 100$. So, 25 million tests at 10$ = 2500 million $ !! And that is just USA ! Europe has about same population So that is X2 for turnover. 5000 million $ & ignores the likely sales in the rest of the world. But I'm new to OBD, happy to see calculations from OBD experts. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
